Biotech

About Biotech

Intima Bioscience is a clinical-stage gene and cell therapy company focused on developing curative treatments for solid tumor cancers. The company operates in the biotechnology sector, specifically targeting the unmet medical needs in oncology. Intima Bioscience's core technology involves the use of CISH, a novel immune checkpoint T cell genetic engineering approach, to enhance the efficacy of T cell therapies in treating solid tumors. The company employs advanced techniques such as CRISPR gene editing to inhibit intracellular immune checkpoints, thereby improving the therapeutic potential of Tumor Infiltrating Lymphocytes (TILs). Intima Bioscience serves patients with metastatic gastrointestinal cancers and other solid tumors, aiming to provide innovative and effective treatment options. The business model revolves around conducting clinical trials to validate their therapies, securing regulatory approvals, and eventually commercializing their treatments. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.